These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 23474348

  • 1. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
    Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL.
    Gynecol Oncol; 2013 Jun; 129(3):452-8. PubMed ID: 23474348
    [Abstract] [Full Text] [Related]

  • 2. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
    Kim KH, Jelovac D, Armstrong DK, Schwartz B, Weil SC, Schweizer C, Alvarez RD.
    Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
    [Abstract] [Full Text] [Related]

  • 3. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    Wang Y, Herrstedt J, Havsteen H, DePoint Christensen R, Mirza MR, Lund B, Maenpaa J, Kristensen G.
    BMC Cancer; 2014 Dec 11; 14():937. PubMed ID: 25494701
    [Abstract] [Full Text] [Related]

  • 4. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
    Vergote I, Armstrong D, Scambia G, Teneriello M, Sehouli J, Schweizer C, Weil SC, Bamias A, Fujiwara K, Ochiai K, Poole C, Gorbunova V, Wang W, O'Shannessy D, Herzog TJ.
    J Clin Oncol; 2016 Jul 01; 34(19):2271-8. PubMed ID: 27001568
    [Abstract] [Full Text] [Related]

  • 5. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T.
    Gynecol Oncol; 2012 Sep 01; 126(3):369-74. PubMed ID: 22659190
    [Abstract] [Full Text] [Related]

  • 6. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S.
    BioDrugs; 2013 Aug 01; 27(4):375-92. PubMed ID: 23728884
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
    Strauss HG, Henze A, Teichmann A, Karbe I, Baumgart A, Thomssen C, Koelbl H.
    Gynecol Oncol; 2007 Mar 01; 104(3):612-6. PubMed ID: 17069876
    [Abstract] [Full Text] [Related]

  • 8. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
    Herzog TJ, Pignata S, Ghamande SA, Rubio MJ, Fujiwara K, Vulsteke C, Armstrong DK, Sehouli J, Coleman RL, Gabra H, Scambia G, Monk BJ, Arranz JA, Ushijima K, Hanna R, Zamagni C, Wenham RM, González-Martín A, Slomovitz B, Jia Y, Ramsay L, Tewari KS, Weil SC, Vergote IB.
    Gynecol Oncol; 2023 Mar 01; 170():300-308. PubMed ID: 36758420
    [Abstract] [Full Text] [Related]

  • 9. Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
    Richardson DL, Moore KN, Vergote I, Gilbert L, Martin LP, Mantia-Smaldone GM, Castro CM, Provencher D, Matulonis UA, Stec J, Wang Y, Method M, O'Malley DM.
    Gynecol Oncol; 2024 Jun 01; 185():186-193. PubMed ID: 38447347
    [Abstract] [Full Text] [Related]

  • 10. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
    Schwandt A, von Gruenigen VE, Wenham RM, Frasure H, Eaton S, Fusco N, Fu P, Wright JJ, Dowlati A, Waggoner S.
    Invest New Drugs; 2014 Aug 01; 32(4):729-38. PubMed ID: 24619298
    [Abstract] [Full Text] [Related]

  • 11. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Nakanishi T, Aoki D, Watanabe Y, Ando Y, Tomotsugu N, Sato Y, Saito T.
    Jpn J Clin Oncol; 2015 May 01; 45(5):422-6. PubMed ID: 25670764
    [Abstract] [Full Text] [Related]

  • 12. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.
    Wenham RM, Lapolla J, Lin HY, Apte SM, Lancaster JM, Judson PL, Gonzalez-Bosquet J, Herschberger A, Havrilesky LJ, Secord AA.
    Gynecol Oncol; 2013 Jul 01; 130(1):19-24. PubMed ID: 23623830
    [Abstract] [Full Text] [Related]

  • 13. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
    Morgan RD, McNeish IA, Cook AD, James EC, Lord R, Dark G, Glasspool RM, Krell J, Parkinson C, Poole CJ, Hall M, Gallardo-Rincón D, Lockley M, Essapen S, Summers J, Anand A, Zachariah A, Williams S, Jones R, Scatchard K, Walther A, Kim JW, Sundar S, Jayson GC, Ledermann JA, Clamp AR.
    Lancet Oncol; 2021 Feb 01; 22(2):277-288. PubMed ID: 33357510
    [Abstract] [Full Text] [Related]

  • 14. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS.
    Lancet Oncol; 2017 Jun 01; 18(6):779-791. PubMed ID: 28438473
    [Abstract] [Full Text] [Related]

  • 15. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
    Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J.
    J Clin Oncol; 2001 Apr 01; 19(7):1901-5. PubMed ID: 11283121
    [Abstract] [Full Text] [Related]

  • 16. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
    Raja FA, Griffin CL, Qian W, Hirte H, Parmar MK, Swart AM, Ledermann JA.
    Br J Cancer; 2011 Sep 27; 105(7):884-9. PubMed ID: 21878941
    [Abstract] [Full Text] [Related]

  • 17. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer.
    Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, Freedman RS.
    Gynecol Oncol; 2009 May 27; 113(2):210-5. PubMed ID: 19264351
    [Abstract] [Full Text] [Related]

  • 18. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
    Herzog TJ, Monk BJ, Rose PG, Braly P, Hines JF, Bell MC, Wenham RM, Secord AA, Roman LD, Einstein MH, Drake RD, Childs BH.
    Gynecol Oncol; 2014 Mar 27; 132(3):517-25. PubMed ID: 24476788
    [Abstract] [Full Text] [Related]

  • 19. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Moore KN, O'Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, Birrer MJ.
    Gynecol Oncol; 2018 Oct 27; 151(1):46-52. PubMed ID: 30093227
    [Abstract] [Full Text] [Related]

  • 20. Role of farletuzumab in epithelial ovarian carcinoma.
    Jelovac D, Armstrong DK.
    Curr Pharm Des; 2012 Oct 27; 18(25):3812-5. PubMed ID: 22591419
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.